AN 215Alternative Names: AN-215
Latest Information Update: 06 Oct 2008
At a glance
- Originator AEterna Zentaris Inc; Tulane University School of Medicine; Zentaris
- Developer AEterna Zentaris GmbH; Tulane University School of Medicine
- Class Antineoplastics
- Mechanism of Action DNA intercalators; Gastrin-releasing peptide inhibitors; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours